PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…

BySenior EditorJune 30, 2022

TOP 20

Top 20 Diagnostics Companies Based on 2021 Revenue

The diagnostic companies continued to serve the high demand for diagnostic testing throughout the COVID-19 pandemic in 2021 Siemens Healthineers, Roche, GE Healthcare, and Abbott were the top players in the race for the global diagnostic companies PharmaShots has compiled a list of the top 20 diagnostics Companies based on their 2021 revenue in the…

ByPrince GiriJune 9, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…

ByPrince GiriFebruary 10, 2022

TOP 20

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy Our team at PharmaShots has compiled a list of top 20 oncology companies based on…

ByPrince GiriSeptember 9, 2021

TOP 20

Top 20 Diagnostics Companies Based on 2020 Revenue

The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world's biggest diagnostics companies being thrust into the limelight Siemens Healthineers- GE Healthcare- Roche- and Abbott are the top players in the race of the global diagnostic companies. The companies are…

ByPrince GiriJune 10, 2021

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 11, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2020

The US FDA has approved 7 NDAs and 2 BLA in Dec 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 105 novel products so far in 2020, including 9 in Dec 2020. Additionally, last year in 2019, the US FDA has approved…

BySenior EditorJanuary 21, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2020

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…

ByDipanshu DixitJanuary 14, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2020

The US FDA has approved 5 NDAs and 1 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 96 novel products so far in 2020, including 6 in Nov 2020.…

BySenior EditorDecember 17, 2020

PharmaShots’ Key Highlights of Second Quarter 2022

Top 20 Diagnostics Companies Based on 2021 Revenue

Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Top 20 Diagnostics Companies Based on 2020 Revenue

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: The US FDA New Drug Approvals in December 2020

PharmaShots’ Key Highlights of Fourth Quarter 2020

Insights+: The US FDA New Drug Approvals in November 2020

Contact US

FOLLOW US